A capable pharmaceutical manufacturer may have an established platform, an inspection history, public registrations or a long product portfolio. None of those facts alone answers the decision that matters to a product holder: whether a named site can responsibly support a defined product, market and timeline. Good partner selection starts by separating public context from controlled project evidence.
1. Treat the presentation as a screening tool, not a conclusion
Public corporate materials can help a prospective partner identify a legal entity, a broad dosage-form platform, a location, selected public records and a possible cooperation direction. That is valuable. It allows both sides to decide whether a non-confidential first discussion is worthwhile.
But a presentation cannot, by itself, establish that a particular product is suitable for a particular line, that current capacity is available, that a registration route will be accepted, or that an agreement has allocated the necessary responsibilities. Under China’s current contract-manufacturing framework, the marketing authorization holder and contracted manufacturer must address pre-acceptance evaluation, technical transfer, quality responsibilities, communication, changes and oversight in a product-specific arrangement. [1] [2]
2. Use three evidence layers
Legal identity, public production scope, dated regulator or government records, and credible third-party records. These are suitable for an initial screen.
Inspection context, public filings, registration records or historical disclosures, read with their date, scope, status and limits.
Product-to-site fit, batch strategy, validation, quality records, current scheduling, dossier roles and commercial conditions—reviewed only after scope and confidentiality are agreed.
The layers are sequential. A public fact may justify a question; it does not answer the controlled question. This distinction protects both sides from turning a marketing phrase into a regulatory or commercial promise.
3. Convert common claims into verification questions
| Public statement | Responsible project question |
|---|---|
| “We have this dosage-form platform.” | Which licensed site, equipment train, process path, container-closure system and product-specific gap assessment apply to the proposed product? |
| “We have international experience.” | Which authority, site, date, scope and status are relevant—and what do they not establish for the target product or market? |
| “We support CMO/CDMO or technology transfer.” | Which development, transfer, analytical, quality and regulatory deliverables are actually in scope, and who owns each decision? |
| “We have strong quality systems.” | What current, product-relevant evidence is available for change control, deviations, CAPA, data governance, release, complaints and oversight? |
| “We can support the proposed timeline.” | What is the critical path, including materials, methods, transfer, validation, filing dependencies, review gates and current scheduling? |
4. Inspection language must stay precise
Inspection terminology is often compressed in marketing materials. It should not be. A responsible review records the inspecting authority, facility, date, scope, classification or outcome, observations, response and current status. “Inspected,” “inspection closed,” “certified,” “approved” and “endorsed” are not interchangeable descriptions. FDA guidance on quality agreements likewise frames outsourced activities around defined responsibilities and controls rather than generic quality labels. [4]
5. A capable project requires more than an available line
For a sterile or other complex product, the core question is whether the receiving site can reproduce the defined product and process with an agreed quality, technical and regulatory control strategy. WHO guidance describes technology transfer as a planned process involving a sending and receiving unit, gap analysis, quality-risk management, trained personnel, documented responsibilities and pre-agreed evidence. [5]
In the China regulatory context, current provincial measures reinforce practical attention to pre-contract site evaluation, quality agreements, materials and product controls, testing, release, stability, deviations, changes, recall, complaints and pharmacovigilance. [2] A subsequent 2026 responsibility list further highlights quality-system, independent quality function, release and pharmacovigilance responsibilities. [3] These sources describe regulated responsibilities; they do not certify any company or project.
6. Start the first discussion with non-confidential facts
An initial conversation does not need a formula, dossier, price target or commercial secret. A concise non-confidential project brief can state the product category, dosage form, intended markets, stage, proposed cooperation model and timing. That is enough to determine whether an NDA and a structured diligence plan are appropriate.
- Product category and dosage form;
- Target country or region and intended regulatory route;
- Development, transfer, commercial or lifecycle stage;
- CMO, CDMO, technology-transfer or registration-support interest;
- Timing window and the decision that must be made next.
Frequently asked questions
Does a licensed dosage form mean a site can accept every project in that form?
No. Product-to-site fit still depends on the exact process, equipment train, materials, container closure, analytical package, validation status, target-market obligations and current project capacity.
Does an inspection record function as a certificate?
No. Authority, site, date, scope, classification and current status must be distinguished. An inspection is not automatically a certification, approval or endorsement.
Can a public capability deck replace an NDA review or site diligence?
No. Public materials are a screening input. Controlled product, quality, technical, regulatory and supply evidence requires an agreed scope and appropriate confidentiality arrangements.
What is useful to share before an NDA?
A non-confidential product category, dosage form, target market, project stage, intended cooperation model and target timing are normally enough for a responsible first discussion.
Authoritative sources
- NMPA — Announcement on Strengthening Supervision and Administration of Contract Manufacturing of Drugs (No. 134, 2025)
- Hainan Medical Products Administration — Measures on MAH responsibility for contract manufacturing and whole-chain quality oversight (2026)
- Hainan Medical Products Administration — Responsibility List for Pharmaceutical Production and Operation Entities (2026)
- U.S. FDA — Contract Manufacturing Arrangements for Drugs: Quality Agreements
- WHO TRS 1044, Annex 4 — Technology transfer in pharmaceutical manufacturing
- European Commission — EU GMP Chapter 7: Outsourced Activities
This article is an industry perspective for general business discussion. It is not legal, regulatory or medical advice, and it does not assess any particular company, site, product or project. Specific requirements must be confirmed with responsible parties and applicable authorities.